Bayer on Friday secured full rights to Loxo Oncology's targeted cancer drug Vitrakvi as well as an earlier-stage compound, exercising an option held by the pharma through a 2017 collaboration deal that predated Eli Lilly's $8 billion buyout of the biotech this past January.